[1] Laperche S,Lefrère JJ,Morel P,et al. Blood transfusion: control of infectious risks[J]. Presse Med,2015,44(2):189-199.
[2] FDA. Guidance for Industry: Nucleic Acid Testing (NAT) to Reduce the Possible Risk of Human Parvovirus B19 Transmission by Plasma-Derived Products. July 2009. Available from: http://www.fda.gov/BiologicsBloodVaccines/GuidanceCompliance RegulatoryInformation/Guidances/Blood/ucm071592.htm.
[3] Council of Europe. European Pharmacopoeia. 6th ed. Strasbourg: Council of Europe Publishing; 2008. Human plasma (pooled and treated for virus inactivation),monograph 1646.
[4] PPTA. QSEAL NAT Testing Standard (Version 2.0). Annapolis (MD): Plasma Protein Therapeutics Association. June 2013. Available from: http://www.pptaglobal.org/images/qseal/NAT TestingV2.pdf.
[5] Cossart YE,Field AM,Cant B,et al. Parvovirus-like particles in human sera[J]. Lancet,1975,1(7898):72-73.
[6] Pattison JR,Jones SE,Hodgson J,et al. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia[J]. Lancet,1981,1(8221):664-665.
[7] Young NS,Brown KE. Parvovirus B19[J]. N Engl J Med,2004,350(6): 586-597.
[8] Lunardi C,Tinazzi E,Bason C,et al. Human parvovirus B19 infection and autoimmunity[J]. Autoimmun Rev,2008,8(2):116-120.
[9] 贾俊婷,马玉媛,向思龙,等. 人细小病毒B19检测技术[J]. 临床输血与检验,2015,17(5):472-477.
[10] Parsyan A,Candotti D. Human erythrovirus B19 and blood transfusion - an update[J]. Transfus Med,2007,17(4):263-278.
[11] Marano G,Vaglio S,Pupella S,et al. Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements[J]. Blood Transfus,2015,13(2):184-196.
[12] Satake M,Hoshi Y,Taira R,et al. Symptomatic parvovirus B19 infection caused by blood component transfusion[J]. Transfusion,2011,51(9):1887-1895.
[13] Kleinman SH,Glynn SA,Lee TH,et al. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion[J]. Blood,2009,114(17): 3677-3683.
[14] Schmidt M,Themann A,Drexler C,et al. Blood donor screening for parvovirus B19 in Germany and Austria[J]. Transfusion,2007,47(10):1775-1782.
[15] Health Council of the Netherlands. Blood Products and Parvovirus B1. Health Council of the Netherlands: The Hague,2002; publication no. 2002/07E.
[16] Geng Y,Wu CG,Bhattacharyya SP,et al. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing[J]. Transfusion,2007,47(5):883-889.
[17] Jia J,Ma Y,Zhao X,et al. Prevalence of human parvovirus B19 in Chinese plasma pools for manufacturing plasma derivatives[J]. Virol J,2015,12:162.
[18] Zhang W,Ke L,Changqing L,et al. Parvovirus B19V DNA contamination in Chinese plasma and plasma derivatives[J]. J Transl Med,2012,10:194. |
